Cinchonine and cinchonidine alleviate cisplatin-induced ototoxicity by regulating PI3K-AKT signaling. 2024

Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, NHC Key Laboratory of Hearing Medicine, Fudan University, Shanghai, China.

OBJECTIVE Cinchonine (CN) and its isomer cinchonidine (CD), two of the common cinchona alkaloids, are wildly used as antimalarial drugs. However, the effects of CN and CD on the auditory system are unknown. METHODS Molecular docking and molecular dynamics (MD) simulation were used for predicting effective drugs. The CCK-8 assay was conducted for assessing cell viability in House Ear Institute-Organ of Corti 1 (HEI-OC1) cells. MitoSox Red staining revealed reactive oxygen species (ROS) amounts. TMRM staining was used to assess the mitochondrial membrane potential (ΔΨm). Immunofluorescence staining of myosin 7a was used to examine hair cells (HCs) in cisplatin-treated neonatal mouse cochlear explants, while TUJ-1 immunostaining was used for the detection of spiral ganglion neurons (SGNs). Cleaved caspase-3 and TUNEL immunostaining were utilized for apoptosis assessment. Immunoblot was carried out to detect PI3K-AKT signaling effectors. RESULTS Pretreatment with CN or CD significantly increased cell viability and reduced mitochondrial dysfunction and ROS accumulation in cisplatin-treated HEI-OC1 cells. Immunofluorescent staining of cochlear explants showed that CN and CD attenuated cisplatin-induced damage to SGNs and HCs. Immunoblot revealed that CN and CD downregulated the expression of cleaved caspase-3 and activated PI3K-AKT signaling in cisplatin-injured HEI-OC1 cells. CONCLUSIONS CD and CN can reduce ototoxicity caused by cisplatin and might help treat cisplatin-associated hearing loss.

UI MeSH Term Description Entries

Related Publications

Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
January 2022, eNeuro,
Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
April 2009, Analytica chimica acta,
Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
January 2019, Analytical cellular pathology (Amsterdam),
Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
May 2019, FEBS open bio,
Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
January 2015, International journal of clinical and experimental pathology,
Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
October 2020, Molecular medicine reports,
Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
March 2021, Journal of cellular physiology,
Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
February 1949, Journal of the American Pharmaceutical Association. American Pharmaceutical Association,
Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
December 2022, Biochimica et biophysica acta. Molecular basis of disease,
Dongmei Tang, and Xue Wang, and Jingfang Wu, and Yimeng Li, and Cai Li, and Xiangyun Qiao, and Li Fan, and Yutao Chen, and Huanhuan Zhu, and Zhiyuan Zhang, and Yingzi He
February 2024, Heliyon,
Copied contents to your clipboard!